PT  - JOURNAL ARTICLE
AU  - María Núñez-Núñez, PharmD, MsC
AU  - Inmaculada Casas-Hidalgo
AU  - Ricardo García-Fumero
AU  - Inmaculada Vallejo-Rodríguez
AU  - Francisco Anguita-Santos
AU  - José Hernández-Quero
AU  - José Cabeza-Barrera
AU  - Andrés Ruiz-Sancho
TI  - Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications
AID  - 10.1136/ejhpharm-2018-001711
DP  - 2018 Nov 26
TA  - European Journal of Hospital Pharmacy
PG  - ejhpharm-2018-001711
4099  - http://ejhp.bmj.com/content/early/2018/11/26/ejhpharm-2018-001711.short
4100  - http://ejhp.bmj.com/content/early/2018/11/26/ejhpharm-2018-001711.full
AB  - Very limited labelled indications have been approved for the newer antimicrobials. Data on the clinical uses, efficacy and safety of dalbavancin are scarce, thus here we sought to describe our clinical experience. 16-month observational prospective study was performed. 19 (86%) were used under off-label indications. 10 (46%) for osteoarticular infections, 5 (23%) bloodstream infections and 3 (14%) endocarditis. To highlight, one patient received dalbavancin as long-term suppressive therapy. Most frequent use reasons were promptly hospital discharge, 11 (65%), and the presence of resistant organisms involving limited treatment options, 5 (23%). Successful outcome was observed in >95% of the patients and only 1 (4.5%) adverse event was reported. Further evidence beyond labelled indications is urgently needed. Despite the limitations, dalbavancin appears to be a safe and efficient option for adult patients who have tried and/or failed other therapies due to multidrug-resistant Gram-positive organisms.